VX 478

Known as: KVX 478, VX-478, Vertex VX478 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2001
0246819952001

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
We conducted a double-blind, placebo-controlled, parallel, dose-escalation trial to evaluate the pharmacokinetics and safety of… (More)
Is this relevant?
1998
1998
Amprenavir (141W94, VX-478, KVX-478) is metabolized primarily by CYP3A4 (cytochrome P450 3A4) in recombinant systems and human… (More)
Is this relevant?
1998
1998
To combat infection and inhibit viral replication of HIV in the brain, antiretroviral agents must cross the blood-brain barrier… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Coadministration with the human immunodeficiency virus (HIV) protease inhibitor ritonavir was investigated as a method for… (More)
Is this relevant?
1996
1996
Mutations in the human immunodeficiency virus (HIV) protease (L90M, G48V, and L90M/G48V) arise when HIV is passaged in the… (More)
Is this relevant?
1996
1996
VX-478 belongs to a novel class of HIV-1 protease inhibitors that are based on N,N-disubstituted benzene sulfonamides. Force… (More)
Is this relevant?
1996
1996
Passage of human immunodeficiency virus type-1 (HIV-1) in T-lymphocyte cell lines in the presence of increasing concentrations of… (More)
Is this relevant?
1995
1995
VX-478 is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) protease (Ki, 0.6 nM) and of HIV-1 replication in… (More)
Is this relevant?
1995
1995
Human immunodeficiency virus type 1 (HIV-1) protease inhibitor-resistant variants, isolated on passage of HIV-1HXB2 in MT-4 cells… (More)
Is this relevant?
1995
1995
Human immunodeficiency virus type 1 (HIV-1) variants with reduced sensitivity to the hydroxyethylamino sulfonamide protease… (More)
Is this relevant?